BitradeX Secures £12 Million Series A to Accelerate Global Expansion of AI-Powered Trading Infrastructure
LONDON--(BUSINESS WIRE)--BitradeX, a next-generation AI-powered digital asset trading platform, has announced the successful completion of its £12 million Series A funding round, led by Bain Capital. The capital will support BitradeX's global compliance expansion, the development of its AI Strategy Labs, and continued investment in its core technology stack.
Founded in 2022, BitradeX is committed to redefining the digital asset trading experience through intelligent automation, rigorous compliance, and a user-first design.
Share
Founded in 2022, BitradeX is committed to redefining the digital asset trading experience through intelligent automation, rigorous compliance, and a user-first design. The platform is best known for its proprietary ARK Trading Model, an AI-native engine built on trillion-parameter architectures that integrates advanced techniques from DeepSeek and Qianfan for high-frequency crypto trading.
The ARK model currently achieves over 90% short-term trend prediction accuracy and has delivered annualized returns of 120%–180% in live market conditions. By combining real-time on-chain activity, macro data, sentiment indicators, and market volatility, ARK executes trades with millisecond latency and dynamic risk calibration.
In a major innovation, BitradeX introduced the industry's first AI-yield-powered Protection Pool, a dual-layer mechanism that autonomously absorbs losses and redistributes excess yields to ensure principal and fixed-income coverage. Unlike traditional insurance-based exchanges, BitradeX embeds capital protection directly into its reward model. The Protection Pool is publicly auditable and seeded with 100 BTC in reserve capital.
On the compliance front, BitradeX holds both a UK FCA crypto license and a US MSB license, operating under institutional-grade custody frameworks, a five-tier risk control system, and a $20 million contingency reserve. These measures enable BitradeX to offer transparent, secure, and compliant services to retail and professional users alike.
Looking ahead, the platform plans to launch AI Strategy Labs in key markets including London, Hong Kong, and Singapore within the next 6 months. These hubs will allow developers and institutions to access and customize the ARK model through open APIs under a 'Strategy-as-a-Service' framework — opening the door to fully modular and programmable crypto trading systems.
BitradeX is positioning itself as the infrastructure layer for the next generation of AI-native finance, delivering predictable performance, automated execution, and built-in protection — all on a globally compliant foundation. If you're interested in collaborating or communicating with Bitradex, please contact us at support@bitradex.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Sakuu Wins Fast Company's 2025 World Changing Ideas Award for Kavian Dry Electrode Printing Process
Honored for platform innovation addressing key bottlenecks in battery manufacturing SAN JOSE, Calif., June 12, 2025--(BUSINESS WIRE)--Sakuu® ( a leading provider of commercial-scale equipment and technologies to the battery manufacturing industry, has been recognized as a winner in Fast Company's 2025 World Changing Ideas Awards for its Kavian dry electrode printing process. The annual awards program honors bold and transformative efforts designed to make the world safer, cleaner, more sustainable, and more equitable. The Sakuu Kavian® Platform is the world's first manufacturing solution to print battery electrodes using dry process, a breakthrough innovation which addresses key industry challenges in scalability, sustainability, safety, and performance, while also reducing cost. "It's a great honor to have Fast Company recognize our dry electrode printing process as a World Changing Idea," said Robert Bagheri, Sakuu founder and CEO. "This award further validates the effectiveness of our Kavian Platform for enabling battery cell producers and OEMs to scale up production to support the growth, sustainability, and efficiency demands of the future." A panel of Fast Company editors and reporters selected 100 outstanding projects from more than 1,500 entries. Applications were judged based on their impact, sustainability, design, creativity, scalability, and ability to improve society, with the competition highlighted in Fast Company's Summer 2025 issue on newsstands June 17. Kavian was specifically honored by judges for "paving the way for safer, more environmentally sustainable battery electrode printing. In comparison to wet methods … Kavian's dry process has a lower environmental impact while achieving equivalent performance." "The World Changing Ideas Awards have always been about showcasing the art of the possible," said Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time." The advantages of Kavian The high-speed, cost-effective Kavian additive manufacturing platform elegantly integrates Sakuu's innovative dry process manufacturing steps into an all-in-one tool to produce a complete lithium-ion (Li-ion) battery electrode using less than half of the factory footprint of conventional wet coating, drying, and calendering equipment. Enabled by the Sakuu team's expertise in material science, Kavian's novel process successfully dry prints cathodes and anodes of various chemistries: NCM, NCA, LFP, graphite, silicon-graphite on current collector foil. This flexibility will also enable new chemistries such as aluminum-ion and sodium-ion. Sakuu has 113 patents (granted and applied) in material, process, and manufacturing, along with 130-plus trade secrets in critical chemistry and process intellectual property (IP). The company has successfully validated the electrochemical performance of its dry printed electrodes, showing Kavian performs equal or better than traditional manufacturing of wet coated electrodes. Benefits in sustainability, cost-savings, and efficiency include: 100% elimination of toxic solvents and water 55% reduction of CO2 emissions 60% smaller footprint for manufacturing floor space 20% reduction in capital equipment costs 30% savings in utility operating costs Sakuu has already delivered hundreds of meters of high-quality dry electrodes to battery cell manufacturing and EV customers. Contact the Sakuu team to request more details on Kavian. About Sakuu Sakuu® is a leading provider of commercial-scale printing equipment and technologies to the battery industry. Sakuu's dry-process platforms enable rapid innovation while reducing waste and avoiding toxins. Headquartered in Silicon Valley, Sakuu's team is transforming manufacturing to power a more sustainable future. As a result, Sakuu was crowned FII8 Innovator 2024 at the Future Investment Initiative Conference in Riyadh and the Kavian Platform was named one of TIME magazine's Best Inventions of 2024. Discover more at View source version on Contacts Sophia De RuntzSterling Communications for Sakuusakuu@
Yahoo
10 minutes ago
- Yahoo
AstroNova Announces Segment Leadership Promotions to Drive Execution of Growth Strategy
WEST WARWICK, R.I., June 12, 2025--(BUSINESS WIRE)--AstroNova, Inc. (Nasdaq: ALOT), a leading innovator in data visualization technology, today announced the promotion of Jorik Ittmann to Senior Vice President of Product Identification. Jorik joins Tom Carll, who was promoted to Senior Vice President of Aerospace, at the end of the first quarter as the leaders of AstroNova's two segments. Both Jorik and Tom will continue to report directly to President and Chief Executive Officer Gregory Woods. Mr. Ittmann and Mr. Carll will be responsible for driving the sales, marketing and operational execution of the Product Identification and Aerospace segments, respectively. Both executives are responsible for and will be compensated on the financial performance of their segments, reinforcing AstroNova's commitment to driving accountability and long-term growth across the organization. Jorik Ittmann, who joined AstroNova in September 2024 as Vice President of Commercial Operations for the Product Identification segment, brings more than 20 years of global sales and business development experience across the healthcare and printing technology industries. Prior to AstroNova, he held senior roles at Zebra Technologies and Health Link Solutions, where he led revenue growth, expanded international markets, and strengthened sales teams. Tom Carll has been a vital member of AstroNova's leadership team since joining the company in 1989. Over the course of his career, he has held a variety of senior positions, including Sales Engineer, National Sales Manager for the Test & Measurement group, and leadership roles within the Aerospace segment since its inception in 2004. "Jorik and Tom have played critical roles in advancing our Product Identification and Aerospace businesses in the last six months and this organizational structure reflects the confidence we have in their continued executional focus," said Greg Woods, President and CEO of AstroNova. "Their expanded responsibilities and new simplified reporting structure will better align execution, support segment growth, and position us to unlock value for our customers and shareholders." About AstroNova AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze, and present data in multiple formats. Its strategy is to drive profitable growth through innovative new technologies, building its installed base to expand recurring revenue while strategically sourcing its replacement products. The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Aerospace segment provides products designed for airborne printing solutions, avionics, and data acquisition. Aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Data acquisition systems are used in research and development, flight testing, missile and rocket telemetry, production monitoring, power, and maintenance applications. For more information please visit: Important Additional Information In connection with its 2025 Annual Meeting of Shareholders, AstroNova has filed a definitive proxy statement with the SEC and caused it to be mailed, together with an annual report and proxy card, to each of our shareholders. The proxy statement and a copy of the other materials that we file with the SEC from time to time, including our Annual Report on Form 10-K, as amended, for the fiscal year ended January 31, 2025, may be obtained free of charge via the Internet at and through the Investor Relations page of our corporate website, In addition, investors and security holders may obtain free copies of the proxy statement, the annual report and other proxy materials by directing a written request to ALOTproxy@ The proxy statement and other relevant materials we have made or will make available contain important information about the director nominees and the other matters to be voted upon by shareholders at the 2025 Annual Meeting of Shareholders. AstroNova urges shareholders to read the proxy statement, and any other relevant materials we make available, before making any decision with respect to the matters to be voted upon at the 2025 Annual Meeting of Shareholders, including the election of directors. View source version on Contacts Investor/Media Contact:Deborah Pawlowski, IRC, Alliance AdvisorsEmail: dpawlowski@ Phone: 716.843.3908
Yahoo
10 minutes ago
- Yahoo
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 SALT LAKE CITY, June 12, 2025--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said "This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future." The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 "With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent," said Dr. Vlasak. "With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations." For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Contacts Pamela Pedrucci PR, Media and External Comms Director HOYA Vision Care Sign in to access your portfolio
